Peripheral Drug Eluting Balloons Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2024-2031

The Global peripheral drug eluting balloons (DEBs) market is poised for substantial growth, with projections indicating a significant expansion in market size by the year 2031. According to recent market research, the peripheral DEB market is forecasted to soar to a value of US$1800 million by 2031, reflecting a remarkable surge from the US$950 million recorded in 2024. This growth trajectory underscores the increasing demand for innovative medical solutions, driven by factors such as technological advancements, rising prevalence of Peripheral Artery Disease (PAD), and a shift towards minimally invasive procedures.

Key Growth Determinants

Advancements in Cardiovascular Treatment: The ongoing advancements in cardiovascular treatment have led to increased adoption of minimally invasive procedures, including peripheral DEBs. These balloons offer a targeted approach to treating PAD by delivering drugs directly to the affected area, thereby improving efficacy and reducing restenosis rates compared to traditional balloons or stents.

Growing Prevalence of Peripheral Artery Disease: The rising prevalence of peripheral artery disease, primarily due to ageing populations and lifestyle factors, is propelling the demand for innovative treatment options like DEBs. As the incidence of PAD continues to rise Globally, there is a corresponding increase in the need for effective and durable treatment solutions, thereby fuelling the growth of the peripheral DEB market.

Shift Towards Minimally Invasive Procedures: Patients and healthcare providers are increasingly preferring minimally invasive procedures over traditional surgical interventions due to benefits such as shorter recovery times, reduced risk of complications, and improved patient outcomes. Peripheral DEBs align with this trend, offering a less invasive alternative for treating PAD compared to surgical options like bypass surgery. This shift towards minimally invasive procedures is expected to contribute significantly to the expansion of the peripheral DEB market.

Major Growth Barriers

Regulatory Hurdles: The market faces stringent regulatory requirements, which can slow down the approval process for new products or expansions into different regions. Compliance with varying regulations across different countries adds complexity and can delay market entry.

Limited Clinical Evidence: Despite their potential benefits, there's still a lack of extensive clinical data supporting the efficacy and safety of peripheral DEBs compared to traditional treatments. This limits physician confidence and adoption, particularly in regions where reimbursement may be tied to demonstrated clinical outcomes.

Cost Constraints: Peripheral DEBs are often priced higher than conventional treatment options such as plain balloons or stents. This cost discrepancy can pose a barrier to adoption, especially in healthcare systems where cost-effectiveness is a major consideration. Reimbursement policies may not fully cover the higher costs associated with DEBs, leading to reluctance from healthcare providers to utilise these devices, particularly in cost-sensitive environments.

Key Trends and Opportunities to Look at

Digital Health Integration: The healthcare industry is increasingly embracing digital technologies to enhance patient care and streamline processes. In the medical device sector, there's a noticeable trend towards integrating digital health features into products. Peripheral drug-eluting balloons (PDEBs) with digital monitoring capabilities could provide real-time data on drug release and patient response, enabling healthcare providers to adjust treatment strategies accordingly.

Focus on Minimally Invasive Procedures: There's a significant shift towards minimally invasive procedures across various medical specialties, including cardiovascular interventions. Patients prefer minimally invasive techniques due to shorter recovery times, reduced risk of complications, and better cosmetic outcomes. PDEBs offer a less invasive alternative to traditional treatment methods for peripheral artery disease (PAD), and other vascular conditions. As the preference for minimally invasive procedures continues to grow, the demand for innovative devices like PDEBs is expected to rise.

Expansion into Emerging Markets: One of the significant opportunities for PDEB manufacturers is expanding their presence in emerging markets. Developing countries are witnessing a rise in the prevalence of cardiovascular diseases due to lifestyle changes, urbanisation, and an ageing population. However, access to advanced medical treatments remains limited in these regions. By tapping into emerging markets, PDEB manufacturers can address unmet medical needs, drive revenue growth, and establish themselves as key players in the Global healthcare landscape.

Regional Frontrunners

1. North America Leads Innovations in Peripheral DEB Market: North America dominates the Global peripheral DEB market due to factors such as high healthcare expenditure, advanced healthcare infrastructure, and early adoption of innovative medical technologies. The region has a substantial patient population suffering from PAD, particularly in the elderly demographic.

2. Europe Experiences Robust Growth, and Advancements in Minimally Invasive Procedures: Europe is another significant market for peripheral DEBs, fuelled by the increasing incidence of PAD and the growing preference for minimally invasive procedures. Countries like Germany, the UK, and France lead the market, supported by well-established healthcare systems and a robust network of healthcare facilities.

3. Asia Pacific Emerges as a High-Potential Market: The Asia Pacific region exhibits immense growth potential in the Peripheral DEB market, attributed to the rising geriatric population, changing lifestyle patterns, and improving healthcare infrastructure. Countries like China, India, and Japan are key contributors to market growth, driven by large patient pools and increasing healthcare expenditure.

Competitive analysis:

• Abbott Laboratories
• Boston Scientific Corporation
• Cook Medical Inc.
• MicroPort Scientific Corporation (Endovastec™)
• Medtronic Plc.
• Cardinal Health, Inc.
• B. Braun Melsungen AG
• BIOTRONIK SE & Co. KG
• Becton, Dickinson and Company
• W. L. Gore & Associates Inc.
• Getinge AB
• Terumo Corp
• Kyoto Medical Planning Co Ltd
• iVascular S.L.U
• AMG International GmbH
• ENDOCOR GmbH
• Meril Life Sciences Pvt. Ltd.
• Nano Therapeutics Pvt Ltd
• Koninklijke Philips N.V.
• REVA Medical

The Global Peripheral Drug Eluting Balloons Market is Segmented as Below:

Drug Coating:

• Paclitaxel Drug Coating
• Sirolimus drug Coating
• Others

Indication:

• Peripheral Arterial Disease
• Peripheral Aneurysms
• In-Stent Restenosis
• Others

Artery Type:

• Carotid Arteries
• Fem-Pop Arteries
• Iliac Arteries
• Infrapop Arteries

End User:

• Hospitals
• Ambulatory Surgical Centres/Outpatients
• Cardiac Catheterization Labs

Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

This product will be delivered within 1-3 business days.